The NIH National Institute of Allergy and Infectious Diseases (NIAID) awarded Advanced BioScience Laboratories (ABL) a contract to provide preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID program staff. The contract has a funding potential of up to $102 million over 10 years.
Under the contract titled, “Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases,” ABL will provide services from early feasibility studies through manufacture of Phase I and II material to close development and production gaps and increase the government's response to emerging disease threats. ABL will also provide appropriate documentation and support for regulatory submissions for Phase I and II clinical testing.
“We are extremely excited at the prospect of applying novel approaches, platforms and technologies in support of NIAID’s mission to develop candidates against a wide range of infectious diseases,” said Thomas VanCott, Ph.D., president and CEO of ABL. “This will be a great opportunity for ABL to develop vaccines and therapies targeting some of the most challenging agents including potential bioterror threats, drug-resistant pathogens, and emerging and re-emerging infectious diseases.”
ABL previously received funding from the NIH National Heart, Lung, and Blood Institute’s Science Moving towards Research Translation and Therapy program in February to manufacture recombinant human lecithin-cholesterol acyltransferase for the treatment of familial LCAT deficiency.